10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.875.1999



# Anti-TLR2 / CD282 Reference Antibody (tomaralimab)

Recombinant Antibody Catalog # APR10310

#### **Product Information**

**Application** FC, Kinetics, Animal Model

89838

Primary Accession 060603

Reactivity Human, Mouse
Clonality Monoclonal
Isotype IgG4

#### **Additional Information**

Target/Specificity TLR2 / CD282

**Endotoxin** 

Calculated MW

**Conjugation** Unconjugated

**Expression system** CHO Cell

**Format** Purified monoclonal antibody supplied in PBS, pH6.0, without

preservative. This antibody is purified through a protein A column.

### **Protein Information**

Name TLR2 ( <u>HGNC:11848</u>)

Synonyms TIL4

**Function** Cooperates with LY96 to mediate the innate immune response to bacterial

lipoproteins and other microbial cell wall components. Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides (PubMed:17889651, PubMed:21078852). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also activate immune cells and promote apoptosis in response to the lipid moiety of lipoproteins (PubMed:10426995, PubMed:10426996). Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6 (PubMed:11441107). Stimulation of monocytes in vitro with M.tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via this receptor, but also partially via TLR4 (PubMed:16622205). MAPK activation in response to bacterial peptidoglycan also occurs via this receptor (PubMed:16622205). Acts as a receptor for M.tuberculosis lipoproteins LprA, LprG, LpqH and PstS1, some lipoproteins are dependent on

other coreceptors (TLR1, CD14 and/or CD36); the lipoproteins act as agonists

to modulate antigen presenting cell functions in response to the pathogen (PubMed:19362712). M.tuberculosis HSP70 (dnaK) but not HSP65 (groEL-2) acts via this protein to stimulate NF-kappa-B expression (PubMed:15809303). Recognizes M.tuberculosis major T-antigen EsxA (ESAT-6) which inhibits downstream MYD88-dependent signaling (shown in mouse) (By similarity). Forms activation clusters composed of several receptors depending on the ligand, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in response to diacylated lipopeptides and TLR2:TLR1:CD14 in response to triacylated lipopeptides (PubMed:16880211). Required for normal uptake of M.tuberculosis, a process that is inhibited by M.tuberculosis LppM (By similarity).


#### **Cellular Location**

Membrane {ECO:0000250 | UniProtKB:Q9QUN7}; Single- pass type I membrane protein. Cytoplasmic vesicle, phagosome membrane {ECO:0000250 | UniProtKB:Q9QUN7}; Single-pass type I membrane protein. Membrane raft. Note=Does not reside in lipid rafts before stimulation but accumulates increasingly in the raft upon the presence of the microbial ligand. In response to diacylated lipoproteins, TLR2:TLR6 heterodimers are recruited in lipid rafts, this recruitment determines the intracellular targeting to the Golgi apparatus. Triacylated lipoproteins induce the same mechanism for TLR2:TLR1 heterodimers.


#### **Tissue Location**

Highly expressed in peripheral blood leukocytes, in particular in monocytes, in bone marrow, lymph node and in spleen. Also detected in lung and in fetal liver. Levels are low in other tissues

## **Images**



Anti-TLR2 / CD282 Reference Antibody (tomaralimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TLR2 / CD282 Reference Antibody (tomaralimab)is more than 100% ,determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.